TERUMO CORP UNSP/ADR

Terumo Corporation’s (TRUMY) wholly-owned subsidiary MicroVention, Inc. recently announced the publication of the Clinical Evaluation of WEB 17 Device in Intracranial Aneurysms (CLEVER) study results. The data from the study assessed the safety and effectiveness of the WEB 17 device in treating both ruptured and unruptured intracranial aneurysms.
The study's findings confirm that the WEB 17 system is as safe and effective as previous generations, with a low complication rate and no rebleeds at both 30 days and one year.
Significance of the Announcement
Data from the CLEVER study evaluating the WEB 17 device in 163 patients across 17 European centers demonstrated that the device maintains a high efficacy rate, with 86.5% adequate occlusion for ruptured aneurysms and 82.4% for unruptured aneurysms at one year.
These results underscore the reliability and safety of the WEB 17 system, reinforcing its position as the most extensively studied intrasaccular device available. With over 200 peer-reviewed publications and seven good clinical practice studies, the WEB device continues to lead in the treatment of wide-neck bifurcation aneurysms, offering a single-device solution that minimizes the need for dual antiplatelet regimens.
This milestone, along with the five-year anniversary of WEB in the United States, highlights Terumo’s commitment to advancing neurovascular care and providing innovative medical technologies that enhance patient outcomes.
More on the WEB Device
In the United States, the WEB Aneurysm Embolization System is approved for treating saccular, wide neck bifurcation intracranial aneurysms located at the middle cerebral artery bifurcation, internal carotid artery terminus, anterior communicating artery complex, or basilar artery apex. It is indicated for aneurysms with a dome diameter of 3 mm to 10 mm and either a neck size of 4 mm or greater or a dome-to-neck ratio greater than 1 and less than 2.
For the European market, the device is intended for the endovascular embolization of both ruptured and unruptured intracranial aneurysms, as well as other neurovascular abnormalities like arteriovenous fistulae. It is also designed for vascular occlusion within the neurovascular system to permanently obstruct blood flow to an aneurysm or other vascular malformation.
The recent development reinforces Terumo’s commitment to advancing neurovascular care by providing innovative and effective treatment options for patients worldwide.
Industry Prospects
Per a report in Future Market Insights, the global cerebral aneurysm management market was valued at $1.56 billion in 2023. It is anticipated to reach $2.98 billion by 2033 at a CAGR of 6.7%.
The market for cerebral aneurysm management in Europe is growing due to a combination of factors such as increasing incidence, advancements in technology, a growing geriatric population, increasing healthcare spending and increased awareness about the condition.
The robust growth is likely due to the rising incidence of cerebral aneurysms worldwide, which is driving demand for effective management and treatment options. The development of minimally invasive techniques such as Surgical Clipping, Endovascular Coiling and Flow Diverter Stenting, and new devices for the treatment of cerebral aneurysms are driving growth in the market.
Other Recent Developments at MicroVention
Earlier this month, MicroVention announced the publication of the SOFAST study. This U.S. prospective, multicenter study evaluated the SOFIA Flow Plus Aspiration Catheter for its efficacy in treating acute ischemic stroke caused by large vessel occlusion.
Last month, MicroVention announced the commercial availability of the LVIS EVO Intraluminal Support Device in the United States for the treatment of wide-neck intracranial aneurysms. The LVIS EVO device features advanced DFT wire construction and braid design, offering enhanced visualization, optimized opening, and precise placement. With the entire stent body fully visible under fluoroscopy, the device provides wall apposition confirmation, ensuring accurate and effective treatment.
Price Performance
Shares of Terumo have increased 4.8% so far this year compared with 4.3% rise of the industry. The S&P 500 witnessed a 17% rise in the same time frame.
Image Source: Zacks Investment Research
Zacks Rank & Key Picks
Currently, Terumo carries a Zacks Rank #4 (Sell).
Some top-ranked stocks in the broader medical space are Quest Diagnostics DGX, Universal Health Services UHS and Haemonetics HAE, each carrying a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Quest Diagnostics has an estimated long-term growth rate of 5.20%. DGX’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 3.67%.
Quest Diagnostics shares have gained 3.2% compared with the industry’s 10.9% rise so far this year.
Universal Health Services has an estimated long-term growth rate of 15.20%. UHS’ earnings surpassed estimates in each of the trailing four quarters, with the average being 8.12%.
Universal Health Services has gained 17.5% compared with the industry's 10.2% rise so far this year.
Haemonetics has an estimated long-term growth rate of 12.00%. HAE’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 13.24%.
Haemonetics’ shares have increased 7.1% compared with the industry's 3.2% rise so far this year.
Zacks’ Top 3 Hydrogen Stocks
Demand for clean hydrogen energy is projected to reach $500 billion by 2030 and grow 5-FOLD by 2050. Want in? Zacks has targeted 3 diversified titans that could lead the way to becoming hydrogen powerhouses.
One has crushed the market over the past 25 years – up +2,400% to +380%.
Another already has capital commitments of $15 billion for low carbon hydrogen products through 2027 alone.
Our third pick soared to 52-week highs in Q4 2023 and has raised its dividend every year for over a decade.
See Stocks Now >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Quest Diagnostics Incorporated (DGX) : Free Stock Analysis Report
Universal Health Services, Inc. (UHS) : Free Stock Analysis Report
Haemonetics Corporation (HAE) : Free Stock Analysis Report
Terumo Corp. (TRUMY) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Terumo (TRUMY) Unit Reveals WEB 17 Device Effective in Aneurysms

Terumo Corporation TRUMY subsidiary MicroVention, Inc. recently announced the results of the SOFAST study in the Journal of Neurointerventional Surgery (JNIS). This prospective, multicenter study evaluated the efficacy and safety of the SOFIA Flow Plus Aspiration Catheter (SOFIA 6F) in treating acute ischemic stroke caused by large vessel occlusion.
Data from the study involving 108 patients showed that 66.7% of the patients experienced good functional outcomes at 90 days after undergoing endovascular stroke thrombectomy procedures. The company stated that the rate of “good clinical outcomes” in the study is among the very best reported with contemporary thrombectomy devices.
Significance of SOFAST
Data from the landmark SOFAST study demonstrates the robust performance of the SOFIA Flow Plus Aspiration Catheter. The catheter system achieved a 75% first-pass mTICI≥2b rate and a high overall revascularization rate of 97.2% at the procedure's end.
The SOFIA system achieved a median time of 12 minutes and 17 minutes for groin puncture to clot contact time and groin puncture to recanalization time, respectively. There was no occurrence of embolization to new territories and symptomatic intracranial hemorrhage rate within 24 hours.
These impressive metrics set a new standard for stroke thrombectomy devices, highlighting the SOFIA Aspiration System's potential to improve patient outcomes in acute ischemic stroke treatment significantly.
MicroVention now offers a fully integrated and streamlined portfolio of stroke solutions, from access to revascularization. Its product lineup includes SOFIA and SOFIA Flow Plus Aspiration Catheters, the ERIC Retrieval Device, the BOBBY Balloon Guide Catheter, the WEDGE Microcatheter, HEADWAY Microcatheters and TRAXCESS Guidewires, ensuring comprehensive care for stroke treatment.
Industry Prospects
Per a report by Verified Market Reports, the global acute ischemic stroke treatment market was worth $9.21 billion in 2023. It is anticipated to reach $19.05 billion by the end of 2030 at a CAGR of 4%
The robust growth is due to the current trends in acute ischemic stroke treatment and diagnosis, highlighting a move toward advanced imaging technologies for timely and precise diagnosis. The increasing popularity of telemedicine and remote monitoring makes timely interventions more accessible. Furthermore, state-of-the-art methods for improving patient outcomes include customized treatment plans and novel therapeutic approaches.
Recent Developments
Last month,MicroVention announced the commercial availability of the LVIS EVO Intraluminal Support Device in the United States for treating wide neck intracranial aneurysms. Available in Europe since 2019, with over 12,000 units sold, the LVIS EVO is the first fully visible coil-assist intracranial stent in the U.S. market. The device features DFT wire construction and an advanced braid design for enhanced visualization, optimized opening and precise placement, ensuring wall apposition confirmation.
Price Performance
Shares of Terumo have risen 6.7% so far this year compared with the industry's 3.7% rise. The S&P 500 has witnessed an 18.2% rise in the same time frame.
Image Source: Zacks Investment Research
Zacks Rank & Key Picks
Currently, Terumo carries a Zacks Rank #4 (Sell).
Some top-ranked stocks in the broader medical space are DaVita Inc. DVA, Universal Health Services UHS and Dexcom DXCM.
DaVita, carrying a Zacks Rank #2 (Buy) at present, has an estimated long-term growth rate of 13.6%. DVA’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 29.4%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
DaVita’s shares have gained 34.2% compared with the industry’s 4.5% rise so far this year.
Universal Health Services, carrying a Zacks Rank of 2 at present, has an estimated long-term growth rate of 14.80%. UHS’ earnings surpassed estimates in each of the trailing four quarters, with the average being 8.12%.
Universal Health Services has gained 20.4% compared with the industry's 17.5% so far this year.
DexCom, carrying a Zacks Rank of 2 at present, has an estimated long-term growth rate of 22.9%. DXCM’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 34.10%.
DexCom’s shares have declined 9.4% against the industry's 3.5% increase so far this year.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Universal Health Services, Inc. (UHS) : Free Stock Analysis Report
DaVita Inc. (DVA) : Free Stock Analysis Report
DexCom, Inc. (DXCM) : Free Stock Analysis Report
Terumo Corp. (TRUMY) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Terumo (TRUMY) Unit's SOFAST Study Shows Positive Results

Terumo Medical Corporation (TRUMY) recently unveiled its AZUR HydroPack Peripheral Coil System in the United States. This marks significant progress in terms of the company's global presence as a leading player in embolotherapy solutions.
The coil system boasts a soft, universal-shaped platinum and hydrogel composition, which distinguishes it prominently in the peripheral coil market.
Advanced Hydrogel Technology
The AZUR HydroPack’s hydrogel technology creates a gel core that promotes new tissue growth, a departure from traditional platinum coils. This unique feature enhances efficiency and minimizes reperfusion, thus advancing patient outcomes.
According to Terumo, the coil's versatility and efficiency provide interventional radiologists and vascular surgeons with an ideal solution for diverse peripheral embolization procedures. With a .018" primary wind and lengths ranging from 5 to 60 cm, it is currently the longest gel core on the market, offering flexible sizing options. According to the company, the soft coil design paired with an enhanced pusher enables ease of delivery, optimized trackability and microcatheter stability.
Image Source: Zacks Investment Research
A Superior Solution
As the market for peripheral coil embolization expands, Terumo's AZUR HydroPack stands out with its advanced design and compatibility with microcatheters. The absence of vessel-diameter sizing requirements, except for the placement of an anchor coil, reduces inventory needs.
The AZUR HydroPack complements Terumo's embolotherapy portfolio, seamlessly fitting in with the AZUR CX Peripheral Coil System and AZUR Framing Coil System.
Market Prospects
Going by a report from Exactitude Consultancy, the embolotherapy market size is set to witness a CAGR of 8.1% from 2023 to 2030. As chronic diseases are becoming more prevalent, the market is expanding, driven by increased incidences of liver cancer and hepatocellular carcinoma. Factors such as the demand for minimally invasive procedures, higher disposable incomes and advanced technological breakthroughs contribute to market growth.
Share Price Performance
Shares of TRUMY have risen 10% in the past year against the industry’s 7.4% decline.
Zacks Rank and Key Picks
Terumo carries a Zacks Rank #4 (Sell) currently.
Some better-ranked stocks in the broader medical space are Insulet (PODD), Haemonetics (HAE) and DexCom (DXCM). While Insulet presently sports a Zacks Rank #1 (Strong Buy), Haemonetics and DexCom each carry a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Estimates for Insulet’s 2023 earnings per share have increased from $1.61 to $1.90 in the past 30 days. Shares of the company have decreased 40.9% in the past year compared with the industry’s decline of 7%.
PODD’s earnings surpassed estimates in all the trailing four quarters, the average surprise being 105.1%. In the last reported quarter, it delivered an average earnings surprise of 77.4%.
Haemonetics’ stock has risen 11.6% in the past year. Earnings estimates for Haemonetics have increased from $3.82 to $3.86 for 2023 and from $4.07 to $4.11 for 2024 in the past 30 days.
HAE’s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 16.1%. In the last reported quarter, it posted an earnings surprise of 5.3%.
Estimates for DexCom’s 2023 earnings per share have increased from $1.23 to $1.41 in the past 30 days. Shares of the company have fallen 7.8% in the past year compared with the industry’s decline of 7.1%.
DXCM’s earnings surpassed estimates in all the trailing four quarters, the average surprise being 36.4%. In the last reported quarter, it delivered an average earnings surprise of 47.1%.
Infrastructure Stock Boom to Sweep America
A massive push to rebuild the crumbling U.S. infrastructure will soon be underway. It’s bipartisan, urgent, and inevitable. Trillions will be spent. Fortunes will be made.
The only question is “Will you get into the right stocks early when their growth potential is greatest?”
Zacks has released a Special Report to help you do just that, and today it’s free. Discover 5 special companies that look to gain the most from construction and repair to roads, bridges, and buildings, plus cargo hauling and energy transformation on an almost unimaginable scale.
Download FREE: How To Profit From Trillions On Spending For Infrastructure >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
To read this article on Zacks.com click here.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

TERUMO CORP UNSP/ADR

Sign up and get access to the forecasts, "shares 360" and dividend history